Several phase III studies have confirmed that patients with advanced lung cancer and EGFR mutations benefit more from first-line targeted EGFR-TKI therapies, such as gefitinib and erlotinib, than from the standard platinum doublet chemotherapy [4]. The gene discussed is EGFR; the disease is lung cancer.